Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study

What Was Tested

This randomized controlled trial looks at Exenatide and Glucagon.

This study evaluated the effects of exenatide, a GLP-1 receptor agonist, and sitagliptin, a DPP-4 inhibitor, on 2-h postprandial glucose (PPG), insulin and glucagon secretion, gastric emptying, and caloric intake in T2D patients.

Who Took Part

PubMed indexes the participants as middle-aged adults, both men and women.

Postprandial glycemic measures were assessed via standard meal test; caloric intake assessed by ad libitum dinner (subset of patients).

How the Study Was Run

In design terms this was a randomized, double-blind and crossover study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Exenatide.

In the crossover set-up each of the participants took both Exenatide and the comparison in turn, acting as their own control.

Gastric emptying was assessed by acetaminophen absorption (Clinicaltrials.gov Registry Number: NCT00477581).

What Was Measured

This study evaluated the effects of exenatide, a GLP-1 receptor agonist, and sitagliptin, a DPP-4 inhibitor, on 2-h postprandial glucose (PPG), insulin and glucagon secretion, gastric emptying, and caloric intake in T2D patients.

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Energy Intake, Exenatide, Glucagon, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Exenatide and Glucagon.

The abstract goes on to report its results in about 10 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2008 (Current medical research and opinion), a journal based in England.

More context: the Exenatide compound page and the Glucagon compound page, all human trials.